Home > Healthcare > Pharmaceuticals > Finished Drug Form > Stomach Cancer Treatment Market

Stomach Cancer Treatment Market Share

Report ID: GMI10227
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Stomach Cancer Treatment Market Share

The stomach cancer therapeutics sector is highly competitive, featuring a mix of major global companies and smaller to medium-sized companies striving for market share. A crucial element of market strategy is the continuous introduction of innovative products utilizing diverse technologies. Leading industry players hold significant influence in this dynamic landscape, often driving advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are vital for strengthening market positions and expanding global footprints amid evolving regulatory landscapes.

Stomach Cancer Treatment Market Companies

Some of the eminent market participants operating in the stomach cancer treatment industry include:

AstraZeneca PLC
Bristol Myers Squibb Company
Bayer AG
Biocon Limited
Celltrion Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Ipsen Pharma
Merck & Co., Inc.
Novartis AG
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The stomach cancer treatment market size was valued at USD 4.7 billion in 2023 and is estimated to grow at 13.5% CAGR from 2024 to 2032, driven by advancements in diagnostic techniques.

The chemotherapy segment of the market is forecasted to reach USD 8.1 billion by 2032, as chemotherapy drugs, administered either orally or intravenously, are designed to kill rapidly dividing cancer cells.

U.S. stomach cancer treatment market is projected to reach USD 5.3 billion by 2032, driven by the rising prevalence of stomach cancer.

AstraZeneca PLC, Bristol Myers Squibb Company, Bayer AG, Biocon Limited, Celltrion Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Ipsen Pharma among others.